NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Apellis Pharmaceuticals, Inc. (APLS) Stock Analysis

Apellis Pharmaceuticals, Inc. (APLS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

APLS

$41.03

$0.00 (0.00%)

Last trade May 15, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare APLS with… →

APLS Key Statistics

As of May 15, 2026
Trading
Open
$41.05
Previous Close
$41.03
52-Week Range
16.61–41.14
Volume
28.64M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.25
Valuation
Market Cap
$5.25B
P/E Ratio
38.35
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.75
EPS (ttm)Profit attributable to each share over the last twelve months.
1.07
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
12.06%
1-Year Return
+150.79%
Dividend and dates
Avg Volume
6.37M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

APLS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+63.34%
2025−21.28%
2024 (partial year)−3.71%

As of May 15, 2026.

APLS Valuation vs Biotechnology Median

Median of 656 stocks
MetricAPLSBiotechnology medianvs median
P/E38.3512.573.1x the median
P/S ratio4.7515.260.3x the median
Profit margin12.06%0.00%12.1 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Apellis Pharmaceuticals, Inc. (APLS) is capitalised at $5.25B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 733 employees.

APLS last closed at $41.03 on May 15, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $16.61 to $41.14. The latest close sits 147.02% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $1.11B. Profit margin runs at 12.06%. That is 12.1 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 1.07.

Valuation Assessment

On trailing earnings, the shares are priced at 38.35 times earnings. That is 3.1 times the Biotechnology median of 12.57. Measured against sales, the shares trade at 4.75 times revenue. On price-to-sales that is 0.3 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is −0.25. Daily returns over the trailing 1 year annualize to a volatility of 148.24%. The trailing one-year price return is +150.79%.

Growth & Income

The record shows no dividend for APLS.

The record holds one complete calendar year, 2025, which returned −21.28%. So far in 2026 the price is +63.34%.

Peer Comparison

Apellis Pharmaceuticals, Inc. (APLS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Apellis Pharmaceuticals, Inc. APLS $5.25B 38.4
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Apellis Pharmaceuticals, Inc. trades at a P/E of 38.4.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of May 15, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts. As of May 14, 2026, Apellis Pharmaceuticals, Inc. operates as a subsidiary of Biogen Inc.

Visit website →